Development of Pharmaceutical Industry in Belarus

The holding company is run by Managing Company of the Holding Company Belpharmprom. The holding company comprises nine organizations, including six manufacturers of medications, one research organization, and one manufacturer of medical goods. The holding company cooperates with 24 pharmaceutical organizations of various types of ownership and departmental affiliation as well as three manufacturers of medical products. The pharmaceutical industry of the Republic of Belarus develops dynamically: while there were 25 manufacturers of medications in 2012, the number rose to 40 in 2024.

The share of medications made by Belpharmprom enterprises in the country’s total output stands at 50%.

In 2024 the output of pharmaceutical products totaled Br986.9 million, 4.9 times as much as in 2012 in actual prices.

Belpharmprom enterprises accounted for over 48% of the country’s export of medications in 2024.

Belpharmprom’s pharmaceutical products are exported to 24 countries. The main target markets are the Russian Federation, Uzbekistan, Kazakhstan, Azerbaijan. and Kyrgyzstan.

Pharmaceutical enterprises are upgraded and retooled on schedule in order to bolster the competitive ability of Belarusian medications. In 2012-2018 the industry implemented 33 investment projects with the volume of investments in excess of $250 million.

Work is in progress to certify the commercial production of medications and pharmaceutical substances for compliance with Good Manufacturing Practices (GMP) of Belarus, countries of the European Union, PIC/S, and the U.S. Food and Drug Administration. About 90% of all the manufacturing lines of Belpharmprom enterprises have been certified already. Certificates to confirm compliance with GMP-PIC/S standards of Ukraine and GMP-EU standards of Romania have been acquired.

Some 5,600 product titles of medications and pharmaceutical substances have been registered in Belarus, including over 1,600 ones of Belarusian make: 1,578 generic ones, 86 original ones, and 22 innovative ones. They belong to different pharmacotherapeutic groups: antitumor drugs, drugs for the treatment of cardiovascular diseases, antifungal drugs, antiviral and antibacterial drugs as well as drugs for the treatment of diseases of the musculoskeletal system, digestive tract, metabolism, and other ones.